Home > Boards > US Listed > Medical - Equipment > BrainsWay (BWAY)

BrainsWay to Report First Quarter 2020 Financial Results

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
midastouch017 Member Profile
 
Followed By 125
Posts 25,552
Boards Moderated 9
Alias Born 02/07/04
160x600 placeholder
Amended Annual and Transition Report (foreign Private Issuer) (20-f/a) Edgar (US Regulatory) - 6/17/2021 5:00:55 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 6/3/2021 9:31:09 AM
Amended Tender Offer Statement by Issuer (sc To-i/a) Edgar (US Regulatory) - 6/3/2021 9:29:07 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 6/2/2021 8:00:58 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 6/1/2021 8:01:06 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 5/24/2021 8:01:03 AM
Brainsway EPS misses by $0.03, beats on revenue Seeking Alpha - 5/20/2021 8:09:26 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 5/20/2021 8:01:04 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 5/5/2021 8:00:57 AM
Tender Offer Statement by Issuer (sc To-i) Edgar (US Regulatory) - 5/4/2021 9:29:32 AM
BrainsWay Announces Social Media Sweepstakes to Celebrate Mental Health Awareness Month GlobeNewswire Inc. - 5/4/2021 9:02:00 AM
BrainsWay launches noninvasive treatment for smoking addiction Seeking Alpha - 4/29/2021 9:10:50 AM
BrainsWay Announces Launch of Noninvasive Treatment for Smoking Addiction to U.S. Providers GlobeNewswire Inc. - 4/29/2021 9:03:00 AM
RIOT, MARA, OCGN and MVIS among notable premarket gainers Seeking Alpha - 4/26/2021 8:21:35 AM
BrainsWay gets FDA clearance for Deep TMS protocol in major depressive disorder treatment Seeking Alpha - 4/26/2021 7:43:06 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 4/26/2021 7:30:54 AM
BrainsWay Receives FDA Clearance for Three-Minute Theta Burst Treatment Protocol for Major Depressive Disorder GlobeNewswire Inc. - 4/26/2021 7:30:00 AM
BrainsWay Announces 100,000 Patients Treated with Deep Transcranial Magnetic Stimulation (Deep TMS) GlobeNewswire Inc. - 4/14/2021 9:03:00 AM
Brainsway EPS beats by $0.03, beats on revenue Seeking Alpha - 3/24/2021 4:24:50 PM
BrainsWay Ltd. Announces Closing of $45.2 Million Underwritten Public Offering of American Depositary Shares Including Full E... GlobeNewswire Inc. - 3/1/2021 7:00:00 AM
BrainsWay Ltd. Announces Pricing of $39,287,000 Underwritten Offering of American Depositary Shares GlobeNewswire Inc. - 2/23/2021 8:30:00 AM
BrainsWay readies ADS offering Seeking Alpha - 2/22/2021 4:06:39 PM
BrainsWay Ltd. Announces Proposed Public Offering of American Depositary Shares GlobeNewswire Inc. - 2/22/2021 4:02:00 PM
BrainsWay Enhances Commercial Leadership Team with the Addition of Fran Hackett as Vice President of North American Sales GlobeNewswire Inc. - 2/16/2021 7:30:00 AM
BrainsWay Reports Preliminary Record Fourth Quarter Revenue and Full-Year 2020 Financial Results GlobeNewswire Inc. - 2/16/2021 7:00:00 AM
midastouch017   Tuesday, 06/09/20 07:54:03 AM
Re: None
Post # of 29 
BrainsWay to Report First Quarter 2020 Financial Results and Operational Highlights on June 24, 2020

GlobeNewswire GlobeNewswire•June 9, 2020

PATTERSON, N.J. and JERUSALEM, Israel, June 09, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced that it will report its first quarter 2020 financial results and operational highlights on June 24, 2020.

The Company will host a conference call at 8:30 AM Eastern Time to review the financial results and operational highlights.

To participate in the conference call, please dial one of the following numbers 10 minutes prior to the start of the call: United States: +1 631-510-7495; International: +44 (0) 2071 928000; and Israel: +972 3-721-7998. The access code for the call is: 6968612.

The conference call will be broadcast live and will be available for replay for 30 days on the Company's website, https://investors.brainsway.com/financial-calendar. Please access the Company's website at least 10 minutes ahead of the conference call to register.

About BrainsWay
BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), for which BrainsWay received marketing authorization from the U.S. Food and Drug Administration (FDA) in 2013 for MDD and in 2018 for OCD. BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences